Intraventricular tissue plasminogen activator for intraventricular hemorrhage caused by an arteriovenous malformation.

Abstract

The use of thrombolytics delivered through an external ventricular drain has improved outcomes in intraventricular hemorrhage, a disease with a poor prognosis; however, presence of an arteriovenous malformation is generally considered a contraindication to thrombolytic use. Due do the high mortality with the current standard of care, thrombolytics should be considered as an acceptable treatment option despite the presence of an arteriovenous malformation in certain clinical situations. We review the available literature and present an additional patient to make the case for the use of thrombolytics for intraventricular hemorrhage from an arteriovenous malformation.

• Authors: Kelley Keefe, Meysam Kebriaei, Andrew Gard, Arun-Angelo Patil
• Journal: Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia (J Clin Neurosci) Vol. 21 Issue 3 Pg. 526-9 (Mar 2014) ISSN: 1532-2653 [Electronic] Scotland
• PMID: 24134809 (Publication Type: Case Reports, Journal Article, Review)
• Copyright: Copyright © 2013 Elsevier Ltd. All rights reserved.

Chemical References

• Fibrinolytic Agents
• Tissue Plasminogen Activator

Topics

• Cerebral Hemorrhage (drug therapy, etiology)
• Female
• Fibrinolytic Agents (administration & dosage)
• Humans
• Infusions, Intraventricular
• Intracranial Arteriovenous Malformations (complications)
• Thrombolytic Therapy (methods)
• Tissue Plasminogen Activator (administration & dosage)
• Young Adult